Skip to main content

Prognostic significance of a complement factor H autoantibody in early stage NSCLC.

Publication ,  Journal Article
Gottlin, EB; Campa, MJ; Gandhi, R; Bushey, RT; Herndon Nd, JE; Patz, EF
Published in: Cancer Biomark
2022

BACKGROUND: Biomarkers that predict which patients with early stage NSCLC will develop recurrent disease would be of clinical value. We previously discovered that an autoantibody to a complement regulatory protein, complement factor H (CFH), is associated with early stage, non-recurrent NSCLC, and hypothesized that the anti-CFH antibody inhibits metastasis. OBJECTIVES: The primary objective of this study was to evaluate the anti-CFH antibody as a prognostic marker for recurrence in stage I NSCLC. A secondary objective was to determine if changes in antibody serum level one year after resection were associated with recurrence. METHODS: Anti-CFH antibody was measured in the sera of 157 stage I NSCLC patients designated as a prognostic cohort: 61% whose cancers did not recur, and 39% whose cancers recurred following resection. Impact of anti-CFH antibody positivity on time to recurrence was assessed using a competing risk analysis. Anti-CFH antibody levels were measured before resection and one year after resection in an independent temporal cohort of 47 antibody-positive stage I NSCLC patients: 60% whose cancers did not recur and 40% whose cancers recurred following resection. The non-recurrent and recurrent groups were compared with respect to the one-year percent change in antibody level. RESULTS: In the prognostic cohort, the 60-month cumulative incidence of recurrence was 40% and 22% among antibody negative and positive patients, respectively; this difference was significant (Gray's test, P= 0.0425). In the temporal cohort, the antibody persisted in the serum at one year post-tumor resection. The change in antibody levels over the one year period was not statistically different between the non-recurrent and recurrent groups (Wilcoxon two-sample test, P= 0.4670). CONCLUSIONS: The anti-CFH autoantibody may be a useful prognostic marker signifying non-recurrence in early stage NSCLC patients. However, change in the level of this antibody in antibody-positive patients one year after resection had no association with recurrence.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Biomark

DOI

EISSN

1875-8592

Publication Date

2022

Volume

34

Issue

3

Start / End Page

385 / 392

Location

Netherlands

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Lung Neoplasms
  • Humans
  • Complement Factor H
  • Carcinoma, Non-Small-Cell Lung
  • Autoantibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gottlin, E. B., Campa, M. J., Gandhi, R., Bushey, R. T., Herndon Nd, J. E., & Patz, E. F. (2022). Prognostic significance of a complement factor H autoantibody in early stage NSCLC. Cancer Biomark, 34(3), 385–392. https://doi.org/10.3233/CBM-210355
Gottlin, Elizabeth B., Michael J. Campa, Rikesh Gandhi, Ryan T. Bushey, James E. Herndon Nd, and Edward F. Patz. “Prognostic significance of a complement factor H autoantibody in early stage NSCLC.Cancer Biomark 34, no. 3 (2022): 385–92. https://doi.org/10.3233/CBM-210355.
Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF. Prognostic significance of a complement factor H autoantibody in early stage NSCLC. Cancer Biomark. 2022;34(3):385–92.
Gottlin, Elizabeth B., et al. “Prognostic significance of a complement factor H autoantibody in early stage NSCLC.Cancer Biomark, vol. 34, no. 3, 2022, pp. 385–92. Pubmed, doi:10.3233/CBM-210355.
Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF. Prognostic significance of a complement factor H autoantibody in early stage NSCLC. Cancer Biomark. 2022;34(3):385–392.

Published In

Cancer Biomark

DOI

EISSN

1875-8592

Publication Date

2022

Volume

34

Issue

3

Start / End Page

385 / 392

Location

Netherlands

Related Subject Headings

  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Lung Neoplasms
  • Humans
  • Complement Factor H
  • Carcinoma, Non-Small-Cell Lung
  • Autoantibodies